Table 3 The correlation between ZBTB16 expression and clinicopathological characteristics of 125 OV patients
Characteristic | No. of patients | ZBTB16 expression | p-value | |
|---|---|---|---|---|
Low (IRS score < 8) | High (IRS score ≥ 8) | |||
Age (n,%) | Â | Â | Â | 0.590 |
 < 55 years | 56 (44.8%) | 33 (26.4%) | 23 (18.4%) | − |
 ≥ 55 years | 69 (55.2%) | 37 (29.6%) | 32 (25.6%) | − |
FIGO stage (n,%) | Â | Â | Â | 0.014 |
 I–II | 45 (36.0%) | 32 (25.6%) | 13 (10.4%) | − |
 III–IV | 80 (64.0%) | 38 (30.4%) | 42 (33.6%) | − |
Pathology stage (n,%) | Â | Â | Â | 0.587 |
 I–II | 54 (43.2%) | 32 (25.6%) | 22 (17.6%) | − |
 III | 71 (56.8%) | 38 (30.4%) | 33 (26.4%) | − |
Histology type (n,%) | Â | Â | Â | 0.068 |
 Serous | 78 (62.4%) | 47 (37.6%) | 31 (24.8%) | − |
 Mucous | 11 (8.8%) | 8 (6.4%) | 3 (2.4%) | − |
 Endometrioid | 14 (11.2%) | 8 (6.4%) | 6 (4.8%) | − |
 Other types | 22 (17.6%) | 7 (5.6%) | 15 (12.0%) | − |
Tumor diameter (n,%) | Â | Â | Â | 0.473 |
  < 10 cm | 62 (49.6%) | 37 (29.6%) | 25 (20.0%) | − |
  ≥ 10 cm | 63(50.4%) | 33 (26.4%) | 30 (24.0%) | − |
Serum CA125 (n,%) | Â | Â | Â | 0.221 |
  < 35 U/ml | 20 (16.0%) | 14 (11.2%) | 6 (4.8%) | − |
  ≥ 35 U/ml | 105 (84.0%) | 56 (44.8%) | 49 (39.2%) | − |